
InMed Pharmaceuticals Inc. (NASDAQ:INM) provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”).
Adolescent patients now eligible to participate in clinical trial